Niagen Bioscience (NAGE) Interest & Investment Income (2010 - 2026)
Niagen Bioscience (NAGE) posted quarterly Interest & Investment Income of $2.0 for Q2 2017, down 99.75% year-over-year from $794.0 in Q2 2016, and up 102.17% quarter-over-quarter from -$92.0 in Q4 2016.
Powered by 
Analysis
Niagen Bioscience (NAGE) Interest & Investment Income (2010 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Interest & Investment Income for 8 consecutive years, with $2.0 the latest figure, recorded in Q2 2017.
- In Q2 2017, Interest & Investment Income fell 99.75% year-over-year to $2.0; the TTM figure through Apr 2017 stood at $1269.0 (down 60.99% YoY), while the FY2025 annual figure was $2.1 million, up 88.4% from the prior year.
- Interest & Investment Income improved to $2.0 in Q2 2017 per NAGE's latest filing, from -$92.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $976.0 in Q4 2015 and bottomed at -$92.0 in Q4 2016.
- Historically, Interest & Investment Income has averaged $514.7 across 5 years, with a median of $605.0 in 2015.
- Annual changes were most pronounced in 2015 — Interest & Investment Income jumped 324.35% — and 2017, when it slumped 99.75%.
- Niagen Bioscience's Interest & Investment Income stood at $884.0 in 2013, then sank by 73.98% to $230.0 in 2014, then surged by 324.35% to $976.0 in 2015, then tumbled by 109.43% to -$92.0 in 2016, then surged by 102.17% to $2.0 in 2017.
- Business Quant data shows NAGE's Interest & Investment Income at $2.0 in Q2 2017, -$92.0 in Q4 2016, and $565.0 in Q4 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Niagen Bioscience | 251.05 Mn | 184.31 Mn | 19.31 Mn | 372,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 372,000.00 |
| Mar 31, 2026 | 375,000.00 |
| Dec 31, 2025 | 552,000.00 |
| Sep 30, 2025 | 564,000.00 |
| Jun 30, 2025 | 552,000.00 |
| Mar 31, 2025 | 459,000.00 |
| Dec 31, 2024 | 373,000.00 |
| Sep 30, 2024 | 276,000.00 |
| Jun 30, 2024 | 241,000.00 |
| Mar 31, 2024 | 239,000.00 |
| Dec 31, 2023 | 282,000.00 |
| Sep 30, 2023 | 188,000.00 |
| Jun 30, 2023 | 125,000.00 |
| Apr 1, 2017 | 2.00 |
| Dec 31, 2016 | 250.00 |
| Oct 1, 2016 | 565.00 |
| Apr 2, 2016 | 794.00 |
| Oct 3, 2015 | 976.00 |
| Jul 4, 2015 | 645.00 |
| Jan 3, 2015 | 838.00 |